SG11201600759XA - Novel quinoline-substituted compound - Google Patents
Novel quinoline-substituted compoundInfo
- Publication number
- SG11201600759XA SG11201600759XA SG11201600759XA SG11201600759XA SG11201600759XA SG 11201600759X A SG11201600759X A SG 11201600759XA SG 11201600759X A SG11201600759X A SG 11201600759XA SG 11201600759X A SG11201600759X A SG 11201600759XA SG 11201600759X A SG11201600759X A SG 11201600759XA
- Authority
- SG
- Singapore
- Prior art keywords
- substituted compound
- novel quinoline
- quinoline
- novel
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 | ||
| PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600759XA true SG11201600759XA (en) | 2016-03-30 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600759XA SG11201600759XA (en) | 2013-08-22 | 2014-08-22 | Novel quinoline-substituted compound |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (hu) |
| EP (1) | EP3037424B1 (hu) |
| JP (1) | JP6161705B2 (hu) |
| KR (1) | KR101906688B1 (hu) |
| CN (1) | CN105683195B (hu) |
| AU (1) | AU2014309788B2 (hu) |
| BR (1) | BR112016003247B1 (hu) |
| CA (1) | CA2922077C (hu) |
| DK (1) | DK3037424T3 (hu) |
| ES (1) | ES2656712T3 (hu) |
| HK (1) | HK1222393A1 (hu) |
| HU (1) | HUE034807T2 (hu) |
| MX (1) | MX370808B (hu) |
| MY (1) | MY182891A (hu) |
| NO (1) | NO3037424T3 (hu) |
| PH (1) | PH12016500225A1 (hu) |
| PL (1) | PL3037424T3 (hu) |
| PT (1) | PT3037424T (hu) |
| RU (1) | RU2689158C2 (hu) |
| SG (1) | SG11201600759XA (hu) |
| TW (1) | TWI603971B (hu) |
| WO (1) | WO2015025936A1 (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
| JOP20190073A1 (ar) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| KR20230145496A (ko) * | 2016-11-17 | 2023-10-17 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| DK3677266T5 (da) * | 2017-09-01 | 2024-08-26 | Taiho Pharmaceutical Co Ltd | Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer |
| TWI837266B (zh) * | 2018-12-28 | 2024-04-01 | 日商大鵬藥品工業股份有限公司 | L718及/或l792突變型治療抗性egfr抑制劑 |
| CN115838369A (zh) | 2019-03-19 | 2023-03-24 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
| CN115181104A (zh) * | 2019-09-29 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| JP2024523861A (ja) | 2021-06-15 | 2024-07-02 | ジェネンテック， インコーポレイテッド | がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用 |
| CN115707704B (zh) * | 2021-08-20 | 2024-09-13 | 广东医诺维申生物技术有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| WO2024121805A1 (en) * | 2022-12-08 | 2024-06-13 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib and process for preparation thereof |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| MX2007011435A (es) * | 2005-03-17 | 2007-12-05 | Novartis Ag | N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf. |
| MY152972A (en) | 2009-07-10 | 2014-12-15 | Taiho Pharmaceutical Co Ltd | Azabicyclo compound and salt thereof |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| JP5792201B2 (ja) * | 2011-01-07 | 2015-10-07 | 大鵬薬品工業株式会社 | 新規二環式化合物又はその塩 |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI594986B (zh) * | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| HUE029343T2 (hu) * | 2012-02-23 | 2017-02-28 | Taiho Pharmaceutical Co Ltd | Kinolil-pirrolo-pirimidil fuzionált gyûrûs vegyületek, valamint sóik |
| WO2014129596A1 (ja) | 2013-02-22 | 2014-08-28 | 大鵬薬品工業株式会社 | 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物 |
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
-
2014
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja active Application Filing
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active IP Right Grant
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/hu unknown
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225A1/en unknown
- 2016-09-06 HK HK16110581.6A patent/HK1222393A1/zh unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249518B (en) | A compound that inhibits trk | |
| HK1222393A1 (zh) | 新的喹啉取代的化合物 | |
| GB201311891D0 (en) | Novel compound | |
| GB201311910D0 (en) | Novel Compounds | |
| GB201311888D0 (en) | Novel compounds | |
| GB201302368D0 (en) | Compound | |
| HK1219100A1 (zh) | 吡啶基吡唑並喹啉化合物 | |
| GB201314926D0 (en) | Novel Compounds | |
| EP2947066A4 (en) | PHENOXYALKYLAMINVERBINDUNG | |
| GB201322512D0 (en) | Novel compounds | |
| EP2970113A4 (en) | NOVEL CONNECTIONS | |
| GB201316762D0 (en) | Novel compounds | |
| GB201316764D0 (en) | Novel compounds | |
| GB201307331D0 (en) | Compound | |
| GB201408643D0 (en) | Compound | |
| GB201322438D0 (en) | Compound | |
| GB201315772D0 (en) | Compound | |
| GB201316100D0 (en) | Novel compounds | |
| GB201305634D0 (en) | Compound | |
| GB201304250D0 (en) | Compound | |
| GB201314477D0 (en) | Novel compounds | |
| GB201314309D0 (en) | Novel Compounds | |
| GB201313933D0 (en) | Novel compounds | |
| GB201301585D0 (en) | Compound | |
| GB201312765D0 (en) | Novel compounds |